bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplemental Figures 1 - 5 from Lung Squamous Cell Carcinomas with Basaloid Histology Represent a Specific Molecular Entity
Authors: Brambilla Christian , Laffaire Julien , Lantuejoul Sylvie , Moro-Sibilot Denis , Mignotte Hélène , Arbib François , Toffart Anne-Claire , Petel Fabien , Hainaut Pierre , Rousseaux Sophie , Khochbin Saadi , de Reyniès Aurélien , Brambilla Elisabeth
Published: April 2023

Supplemental Figure 1: Embryonic stem cell-like gene expression signatures in Basaloid tumors. Supplemental Figure 2: DNA copy number aberrations in the CIT cohort. Supplementary Figure 3: Consensus classification of the expression profiles of tumor samples in the CIT cohort. Supplemental Figure 4: Kaplan-Meier curves in the CIT cohort according to CIT molecular subtypes. Supplemental Figure 5: Kaplan-Meier curves of overall survival in 7 validation public datasets according to CIT molecular subtypes and Wilkerson et al. subtypes.
Supplemental Figure S4 from Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Authors: Nguyen Le Xuan Truong , Zhu Li , Lee Yunqin , Ta Lynn , Mitchell Beverly S.
Published: April 2023

Supplemental Figure S4. Effects of Ebp1 overexpression on rRNA synthesis and cell proliferation in MEF Ebp1 -/-cells.
SUPPLEMENTARY DATA from A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma
Authors: Evens Andrew M. , Balasubramanian Sriram , Vose Julie M. , Harb Wael , Gordon Leo I. , Langdon Robert , Sprague Julian , Sirisawad Mint , Mani Chitra , Yue Jeanne , Luan Ying , Horton Sharon , Graef Thorsten , Bartlett Nancy L.
Published: April 2023

SUPPLEMENTAL APPENDIX Supplemental Table 1. Phase I Abexinostat Dosing Schedule and Dose Levels. Supplemental Table 2. Dose-Limiting Toxicities. Supplemental Table 3. Adverse Events of {greater than or equal to} Grade 3 (Phase I All-treated Population). Supplemental Table 4. Adverse Events of {greater than or equal to} Grade 3 (Phase II All-treated Population)
Supplementary Table 1 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 61K, Supplementary table 1. Descriptive statistics of Vdelta1+ and Vdelta2+ gammadeltaT cell expansion within 14 days in response to various immobilised anti-gammadeltaTCR antibodies or IPP.
Supplementary Figure Legends from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 98K
Supplementary Figure legend from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

Supplementary Figure legend
Supplementary Figure S4 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

Silencing c-Myc impaired glucose metabolism in PDAC cell lines.
Supplementary Figure S3 from FBW7 (F-box and WD Repeat Domain-Containing 7) Negatively Regulates Glucose Metabolism by Targeting the c-Myc/TXNIP (Thioredoxin-Binding Protein) Axis in Pancreatic Cancer
Authors: Ji Shunrong , Qin Yi , Liang Chen , Huang Run , Shi Si , Liu Jiang , Jin Kaizhou , Liang Dingkong , Xu Wenyan , Zhang Bo , Liu Liang , Liu Chen , Xu Jin , Ni Quanxing , Chiao Paul J. , Li Min , Yu Xianjun
Published: April 2023

TXNIP knockdown can reverse the effects of FBW7 overexpressing in vitro.
Supplementary Figure 3 from Neuroblastoma Killing Properties of Vδ2 and Vδ2-Negative γδT Cells Following Expansion by Artificial Antigen-Presenting Cells
Authors: Fisher Jonathan P.H. , Yan Mengyong , Heuijerjans Jennifer , Carter Lisa , Abolhassani Ayda , Frosch Jennifer , Wallace Rebecca , Flutter Barry , Capsomidis Anna , Hubank Mike , Klein Nigel , Callard Robin , Gustafsson Kenth , Anderson John
Published: April 2023

PDF file - 89K, Supplementary figure 3. Variation in gammadeltaTCR repertoire before expansion stimulus applied.
Supplementary Methods from Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy
Authors: Sterman Daniel H. , Alley Evan , Stevenson James P. , Friedberg Joseph , Metzger Susan , Recio Adri , Moon Edmund K. , Haas Andrew R. , Vachani Anil , Katz Sharyn I. , Sun Jing , Heitjan Daniel F. , Hwang Wei-Ting , Litzky Leslie , Yearley Jennifer H. , Tan Kay See , Papasavvas Emmanouil , Kennedy Paul , Montaner Luis J. , Cengel Keith A. , Simone Charles B. , Culligan Melissa , Langer Corey J. , Albelda Steven M.
Published: April 2023

Additional Trial related information and methods
Supplementary Table 3 from Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival
Authors: Yap Kai Lee , Kiyotani Kazuma , Tamura Kenji , Antic Tatjana , Jang Miran , Montoya Magdeline , Campanile Alexa , Yew Poh Yin , Ganshert Cory , Fujioka Tomoaki , Steinberg Gary D. , O'Donnell Peter H. , Nakamura Yusuke
Published: April 2023

Clinical characteristics of the 81 patients, according to recurrence status.
Supplementary Table 2 from Whole-Exome Sequencing of Muscle-Invasive Bladder Cancer Identifies Recurrent Mutations of UNC5C and Prognostic Importance of DNA Repair Gene Mutations on Survival
Authors: Yap Kai Lee , Kiyotani Kazuma , Tamura Kenji , Antic Tatjana , Jang Miran , Montoya Magdeline , Campanile Alexa , Yew Poh Yin , Ganshert Cory , Fujioka Tomoaki , Steinberg Gary D. , O'Donnell Peter H. , Nakamura Yusuke
Published: April 2023

Normal adjacent bladder tissue specimens (formal pathologist review).
Supplementary Tables 2 - 4 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Authors: Wynes Murry W. , Hinz Trista K. , Gao Dexiang , Martini Michael , Marek Lindsay A. , Ware Kathryn E. , Edwards Michael G. , Böhm Diana , Perner Sven , Helfrich Barbara A. , Dziadziuszko Rafal , Jassem Jacek , Wojtylak Szymon , Sejda Aleksandra , Gozgit Joseph M. , Bunn Paul A. , Camidge D. Ross , Tan Aik-Choon , Hirsch Fred R. , Heasley Lynn E.
Published: April 2023

PDF file - 90KB, Table S2. Tabulated expression values for selected FGFs in lung cancer cell lines from the Cancer Cell Line Encyclopedia. Table S3. Tabulated FGFR1 gene copy number values determined by SISH and associated patient data for the surgical lung cancer cohort. Table S4. Tabulated FGFR1 mRNA expression values determined by ISH and associated patient data for the surgical lung cancer cohort.
Supplementary Table 1 from FGFR1 mRNA and Protein Expression, not Gene Copy Number, Predict FGFR TKI Sensitivity across All Lung Cancer Histologies
Authors: Wynes Murry W. , Hinz Trista K. , Gao Dexiang , Martini Michael , Marek Lindsay A. , Ware Kathryn E. , Edwards Michael G. , Böhm Diana , Perner Sven , Helfrich Barbara A. , Dziadziuszko Rafal , Jassem Jacek , Wojtylak Szymon , Sejda Aleksandra , Gozgit Joseph M. , Bunn Paul A. , Camidge D. Ross , Tan Aik-Choon , Hirsch Fred R. , Heasley Lynn E.
Published: April 2023

XLSX file - 66KB, Table S1. Compiled and tabulated ponatinib IC50 values, FGF and FGFR expression, FGFR1 gene copy number and characteristics of the 58 lung cancer cell lines.
Supplementary table 7 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

Combined multivariate analyses of HPV16 DNA, cancer stem cell markers, hypoxia and additional prognostic factors for all patients (endpoint loco-regional control). HR = hazard ratio; 95% CI = 95 percent confidence interval; ECE = extracapsular extension.
Supplementary table 3 from Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(−) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG
Authors: Linge Annett , Löck Steffen , Gudziol Volker , Nowak Alexander , Lohaus Fabian , von Neubeck Cläre , Jütz Martin , Abdollahi Amir , Debus Jürgen , Tinhofer Inge , Budach Volker , Sak Ali , Stuschke Martin , Balermpas Panagiotis , Rödel Claus , Avlar Melanie , Grosu Anca-Ligia , Bayer Christine , Belka Claus , Pigorsch Steffi , Combs Stephanie E. , Welz Stefan , Zips Daniel , Buchholz Frank , Aust Daniela E. , Baretton Gustavo B. , Thames Howard D. , Dubrovska Anna , Alsner Jan , Overgaard Jens , Baumann Michael , Krause Mechthild
Published: April 2023

Multivariate analyses of hypoxia-gene signatures and additional prognostic factors assessed for all patients. HR = hazard ratio; 95% CI = 95 percent confidence interval; ECE = extracapsular extension.
Table S3 from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

Gene ontology description of the 28 G12V unique proteins shown in Figure 2B
Table S2 from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

List of differentially secreted proteins between the 2D and 3D secretomes of SW48 parental cells
Table S1 from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

Clinical characteristics of patients
SupplementaryMaterial from Circulating pEGFR Is a Candidate Response Biomarker of Cetuximab Therapy in Colorectal Cancer
Authors: Katsila Theodora , Juliachs Mercè , Gregori Josep , Macarulla Teresa , Villarreal Laura , Bardelli Alberto , Torrance Chris , Elez Elena , Tabernero Josep , Villanueva Josep
Published: April 2023

It contains supplementary Experimental Procedures and Suppl. figures
Supplemental table 1: Semi-quantitative immunohistochemical (IHC) analysis of s.c. DLBCL cell line xenografts. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

To investigate whether the expression level of BCL2 proteins detected by western blot is comparable with the expression level assessed by IHC analysis, we analyzed protein expression (by IHC) of BCL2, MCL1 and BCL-XL from subcutaneous lymphoma xenografts obtained from mice xenotransplanted with selected DLBCL cell lines with known protein expression (by western blot).
Supplemental figure 5 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Authors: Zhang Ling , Morgan Richard A. , Beane Joal D. , Zheng Zhili , Dudley Mark E. , Kassim Sadik H. , Nahvi Azam V. , Ngo Lien T. , Sherry Richard M. , Phan Giao Q. , Hughes Marybeth S. , Kammula Udai S. , Feldman Steven A. , Toomey Mary Ann , Kerkar Sid P. , Restifo Nicholas P. , Yang James C. , Rosenberg Steven A.
Published: April 2023

Supplemental figure 5. Treg reconstitution. Shown are the percentages of circulating T cells with a phenotype consistent with a Treg cell (CD4+/CD25+/FoxP3+). Data from parallel TIL trial using TIL administration but without exogenous IL2 support (TIL No IL2) and TIL engineered with the NFAT.IL2 vector (TIL IL12).
Supplemental figure 5: Additional cytotoxic mechanism of action of HHT in DLBCL. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

Downregulation of MYC, cFLIP or BCL6 in OCI-Ly7 and BJAB DLBCL cell lines (by western blot) after exposure to HHT.
Supplemental figure 4: Comparison of sensitivity of 18 DLBCL cell lines to HHT, ABT-199 and ABT-737. from Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma
Authors: Klanova Magdalena , Andera Ladislav , Brazina Jan , Svadlenka Jan , Benesova Simona , Soukup Jan , Prukova Dana , Vejmelkova Dana , Jaksa Radek , Helman Karel , Vockova Petra , Lateckova Lucie , Molinsky Jan , Maswabi Bokang Calvin Lenyeletse , Alam Mahmudul , Kodet Roman , Pytlik Robert , Trneny Marek , Klener Pavel
Published: April 2023

The graphs show the extent of apoptosis of DLBCL cell lines induced by different concentrations of HHT, ABT-199 and ABT-737 after 24hrs exposure to particular agents.
Supplemental figure 2 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Authors: Zhang Ling , Morgan Richard A. , Beane Joal D. , Zheng Zhili , Dudley Mark E. , Kassim Sadik H. , Nahvi Azam V. , Ngo Lien T. , Sherry Richard M. , Phan Giao Q. , Hughes Marybeth S. , Kammula Udai S. , Feldman Steven A. , Toomey Mary Ann , Kerkar Sid P. , Restifo Nicholas P. , Yang James C. , Rosenberg Steven A.
Published: April 2023

Supplemental figure 2. Phenotype of NFAT.IL12 gene modified TIL compared to matched untransduced TIL.Shown are the percentage of cells with a phenotype consistent with effector memory (CD62L-CD45RA-),central memory (CD62L+CD45RA-), Naive (CD62+, CD45RA+) and EMRA (CD62L-CD45RA+).UT, untransduced.
Supplemental figure 1 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Authors: Zhang Ling , Morgan Richard A. , Beane Joal D. , Zheng Zhili , Dudley Mark E. , Kassim Sadik H. , Nahvi Azam V. , Ngo Lien T. , Sherry Richard M. , Phan Giao Q. , Hughes Marybeth S. , Kammula Udai S. , Feldman Steven A. , Toomey Mary Ann , Kerkar Sid P. , Restifo Nicholas P. , Yang James C. , Rosenberg Steven A.
Published: April 2023

Supplemental figure 1. Gene transfer efficiency. Shown are 6 representative determinations of NFAT.IL12 transduction efficiency. NFAT.IL2 engineered TIL cultures were stimulated by PMA/ionomycin and then subject to surface staining for CD3 and intracellular staining for IL-12 with resultant scatter plots shown. The patient numbers and response were as labeled with the percent IL-12+ cells shown. UT, untransduced.
Supplementary table from Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma
Authors: Gao Huiping , Li Kesang , Tu Hong , Pan Xiaorong , Jiang Hua , Shi Bizhi , Kong Juan , Wang Hongyang , Yang Shengli , Gu Jianren , Li Zonghai
Published: April 2023

Supplementary table. Primer sequences used for construction of the different CARs using the splicing PCR by overlap extension technique.
supplementary figure legend from Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab
Authors: Napolitano Stefania , Martini Giulia , Rinaldi Barbara , Martinelli Erika , Donniacuo Maria , Berrino Liberato , Vitagliano Donata , Morgillo Floriana , Barra Giusy , De Palma Raffaele , Merolla Francesco , Ciardiello Fortunato , Troiani Teresa
Published: April 2023

supplementary figure legend
Supplementary Tables from A Validated Prognostic Multigene Expression Assay for Overall Survival in Resected Colorectal Cancer Liver Metastases
Authors: Balachandran Vinod P. , Arora Arshi , Gönen Mithat , Ito Hiromichi , Turcotte Simon , Shia Jinru , Viale Agnes , Snoeren Nikol , van Hooff Sander R. , Rinkes Inne H.M. Borel , Adam René , Kingham T. Peter , Allen Peter J. , DeMatteo Ronald P. , Jarnagin William R. , D'Angelica Michael I.
Published: April 2023

Univariate and multivariate analyses of recurrence free survival in derivation (Table 1) and validation (Table 2) cohorts.
Supplementary Figures from Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients
Authors: Garner Andrew P. , Gozgit Joseph M. , Anjum Rana , Vodala Sadanand , Schrock Alexa , Zhou Tianjun , Serrano Cesar , Eilers Grant , Zhu Meijun , Ketzer Julia , Wardwell Scott , Ning Yaoyu , Song Youngchul , Kohlmann Anna , Wang Frank , Clackson Tim , Heinrich Michael C. , Fletcher Jonathan A. , Bauer Sebastian , Rivera Victor M.
Published: April 2023

Supplementary Figures. Figure S1. Chemical structures of imatinib, sunitinib, regorafenib and ponatinib. Figure S2. Expression and activation of KIT in engineered Ba/F3 cells. Figure S3. Ponatinib inhibits the phosphorylation of exon 11primary activating, and secondary resistant mutant forms of KIT. Figure S4. Secondary mutants reduce ponatinib potency in Ex9 ins and V560D cell lines. Figure S5. Illustration of the optimal fit of ponatinib to KIT. Figure S6. Impact of compound treatment on KIT signaling in GIST-derived cell lines.
Supplementary Table 2 from Extracellular Lumican Inhibits Pancreatic Cancer Cell Growth and Is Associated with Prolonged Survival after Surgery
Authors: Li Xinqun , Truty Mark A. , Kang Ya'an , Chopin-Laly Xavier , Zhang Ran , Roife David , Chatterjee Deyali , Lin E. , Thomas Ryan M. , Wang Huamin , Katz Matthew H. , Fleming Jason B.
Published: April 2023

Univariate analysis of factors associated with overall survival, recurrence-free survival, and liver-specific recurrence-free survival.
Supplementary Figure 2 from Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα–Driven Leukemia
Authors: Coltella Nadia , Valsecchi Roberta , Ponente Manfredi , Ponzoni Maurilio , Bernardi Rosa
Published: April 2023

Supplementary Figure 2: High doses EZN-2208 induce apoptosis in leukemic bone marrow cells.
Supplementary Table S2 from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

The top 50 most significant hits from cDNA microarray analysis
Supplemental Table S5 from Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas
Authors: Morin Ryan D. , Assouline Sarit , Alcaide Miguel , Mohajeri Arezoo , Johnston Rebecca L. , Chong Lauren , Grewal Jasleen , Yu Stephen , Fornika Daniel , Bushell Kevin , Nielsen Torsten Holm , Petrogiannis-Haliotis Tina , Crump Michael , Tosikyan Axel , Grande Bruno M. , MacDonald David , Rousseau Caroline , Bayat Maryam , Sesques Pierre , Froment Remi , Albuquerque Marco , Monczak Yury , Oros Kathleen Klein , Greenwood Celia , Riazalhosseini Yasser , Arseneault Madeleine , Camlioglu Errol , Constantin André , Pan-Hammarstrom Qiang , Peng Roujun , Mann Koren K. , Johnson Nathalie A.
Published: April 2023

Targeted sequencing of untreated DLBCL and TLy
Figure legends (supplementary figures) from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

Figure legends for Figure S1-S4
Figure S4 from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

SERPINE1 expression detected by immunohistochemistry in FTC236-Notch1 xenografts with or without Notch1 induction. (A) and (B). Two representative tumors from the group without Notch1 induction (Dox-); (C) and (D). Two representative tumors from the group with Notch1 induction (Dox+). Weaker staining of SERPINE1 (1+) is shown in the Dox+ tumors compared with 3+ staining in Dox- tumors. "Dox" indicates doxycycline; Scale bar: 50µm.
Supplementary Figures Legends from Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
Authors: Kim Hyung Suk , Jeong Chang Wook , Kwak Cheol , Kim Hyeon Hoe , Ku Ja Hyeon
Published: April 2023

Supplementary Legends
Supplementary Figure 3 from Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis
Authors: Kim Hyung Suk , Jeong Chang Wook , Kwak Cheol , Kim Hyeon Hoe , Ku Ja Hyeon
Published: April 2023

Probability bar plots (rankograms) for the neo-adjuvant chemotherapy network. The regimens were ranked according to the surface under the cumulative ranking curve (SUCRA) values. The possible rank of each treatment (from best to worse according to the outcome) is shown on the horizontal axis. The size of each bar corresponds to the probability of each treatment to be at a specific rank.
Figure S1 from Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression
Authors: Yu Xiao-Min , Jaskula-Sztul Renata , Georgen Maria R. , Aburjania Zviadi , Somnay Yash R. , Leverson Glen , Sippel Rebecca S. , Lloyd Ricardo V. , Johnson Brian P. , Chen Herbert
Published: April 2023

The correlation between age and expression levels of Notch1 in primary DTC samples (A), contra-lateral non-tumor tissues (B) and tissue of benign thyroid disease (C).(A) Scatter plot of negative linear correlation between Notch1 levels and age in primary DTC samples (R = -0.495). (B)-(C) Significant linear correlation was not observed between age and Notch1 levels in the non-tumor tissues or benign thyroid lesions. Pearson's correlation test was used to compute the correlation significance between the 2 variables.
Supplementary Figure 1B from Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
Authors: Sanmamed Miguel F. , Carranza-Rua Omar , Alfaro Carlos , Oñate Carmen , Martín-Algarra Salvador , Perez Guiomar , Landazuri Sara F. , Gonzalez Álvaro , Gross Stefanie , Rodriguez Inmaculada , Muñoz-Calleja Cecilia , Rodríguez-Ruiz María , Sangro Bruno , López-Picazo José M. , Rizzo Manglio , Mazzolini Guillermo , Pascual Juan I. , Andueza Maria Pilar , Perez-Gracia Jose Luis , Melero Ignacio
Published: April 2023

Supplementary Figure 1B. Time course of the serum concentrations of IL-8 (lower panels) and tumor volume (upper panels) in Rag2-/-IL2RÃŽÂ³c-/- mice xenografted with the indicated cell lines. Individual mice are represented and at the time point indicated by the arrow the tumor was surgically removed. Serum IL-8 concentrations are depicted at 2h and 24h after surgery.
Supplementary Figure 3S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Anti-SEA/E-120 concentration in ITT and the subgroup SG at baseline and immediately before Nap cycle 2 (week 9), before Nap cycle 3 (week 17) and at week 25. Median{plus minus}SE is depicted.
Supplementary Figure 1S from A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Authors: Hawkins Robert E. , Gore Martin , Shparyk Yaroslav , Bondar Vladimir , Gladkov Oleg , Ganev Tosho , Harza Mihai , Polenkov Serhii , Bondarenko Igor , Karlov Petr , Karyakin Oleg , Khasanov Rustem , Hedlund Gunnar , Forsberg Goran , Nordle Örjan , Eisen Timothy
Published: April 2023

Overlapping anti-SEA/E-120 windows in Moving median and adapted Subpopulation Treatment Effect Pattern Plot (STEPP) analysis. Anti-SEA/E-120 by blocks where min, median and max values are depicted
Supplementary Figures from Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients
Authors: Wang Peilu , Bahreini Amir , Gyanchandani Rekha , Lucas Peter C. , Hartmaier Ryan J. , Watters Rebecca J. , Jonnalagadda Amruth R. , Trejo Bittar Humberto E. , Berg Aaron , Hamilton Ronald L. , Kurland Brenda F. , Weiss Kurt R. , Mathew Aju , Leone Jose Pablo , Davidson Nancy E. , Nikiforova Marina N. , Brufsky Adam M. , Ambros Tadeu F. , Stern Andrew M. , Puhalla Shannon L. , Lee Adrian V. , Oesterreich Steffi
Published: April 2023

Supplementary Figure S1A. Pre-amplification preserves mutant allele frequency and maintains sensitivity of ESR1-D538G mutation detection by ddPCR. Supplementary Figure S1B. Pre-amplification preserves mutant allele frequency and maintains sensitivity of PIK3CA-E545K mutation detection by ddPCR. Supplementary Figure S2. ESR1 Y537C/N/S and D538G mutation probes are specific to their corresponding mutations. Supplementary Figure S3. Specificity of Probes Supplementary Figure S4. LLoD determination of ddPCR on A) Frozen tissues, B) cfDNA, and C) FFPE tissues. Supplementary Figure S5. Mutant allele frequency of PIK3CA H1047R mutation in 12 bone metastases. Supplementary Figure S6. The D538G ER mutation in 3 brain mets was confirmed by Sanger sequencing. Supplementary Figure S7. ESR1 Y537S and D538G observed in the same specimens are not mutated on the same alleles. Supplementary Figure S8. Clinical timelines and allele frequency of ESR1 mutations in multiple blood draws and matched metastatic lesions from two patients.
Supplemental Figure 3 from BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Authors: Olow Aleksandra , Mueller Sabine , Yang Xiaodong , Hashizume Rintaro , Meyerowitz Justin , Weiss William , Resnick Adam C. , Waanders Angela J. , Stalpers Lukas J.A. , Berger Mitchel S. , Gupta Nalin , James C. David , Petritsch Claudia K. , Haas-Kogan Daphne A.
Published: April 2023

Combinatorial index and median-effect plots for BRAFWT cell lines.
Figure S5 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Figure S5. Daratumumab activity in a CLL-PDX model.
Supplemental Figure 1 from BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas
Authors: Olow Aleksandra , Mueller Sabine , Yang Xiaodong , Hashizume Rintaro , Meyerowitz Justin , Weiss William , Resnick Adam C. , Waanders Angela J. , Stalpers Lukas J.A. , Berger Mitchel S. , Gupta Nalin , James C. David , Petritsch Claudia K. , Haas-Kogan Daphne A.
Published: April 2023

Combinatorial index and median-effect plots for BRAFV600E mutated cell lines.
Figure S1 from The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia
Authors: Matas-Céspedes Alba , Vidal-Crespo Anna , Rodriguez Vanina , Villamor Neus , Delgado Julio , Giné Eva , Roca-Ho Heleia , Menéndez Pablo , Campo Elías , López-Guillermo Armando , Colomer Dolors , Roué Gaël , Wiestner Adrian , Parren Paul W.H.I. , Doshi Parul , van Bueren Jeroen Lammerts , Pérez-Galán Patricia
Published: April 2023

Figure S1. Effect of CRPs blockade on daratumumab-induced CDC. Daudi and CLL cells were labeled with Calcein-AM (1μM) and challenged to CDC induction by daratumumab (DARA), rituximab (RITUX), ofatumumab (OFA) or isotype control, all of them at 10μg/mL, in the presence of 10% Normal Human Serum (NHS).
Supplemental Figures 6 and 7 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

R3Mab reduces serum levels of human MMP-1 and pro-MMP-10 in mice bearing bladder tumor xenografts.
Suppl. Fig. 6 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

Effect of TMI-005 and IR alone and in combination on the growth of A549-derived tumor xenografts.
Supplemental Figure 3 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

FGFR3 knockdown in RT112 cells reduces total MMP-10 protein level in conditioned medium.
Supplemental Figure 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
Authors: Du Xiangnan , Lin Benjamin C. , Wang Qian-Rena , Li Hao , Ingalla Ellen , Tien Janet , Rooney Isabelle , Ashkenazi Avi , Penuel Elicia , Qing Jing
Published: April 2023

FGFR3 siRNA and R3Mab diminish MMP-1 and MMP-10 mRNA leves in UMUC-14 cells.
Suppl. Fig. 3 from Secretome Signature Identifies ADAM17 as Novel Target for Radiosensitization of Non–Small Cell Lung Cancer
Authors: Sharma Ashish , Bender Sabine , Zimmermann Martina , Riesterer Oliver , Broggini-Tenzer Angela , Pruschy Martin N.
Published: April 2023

Targeting of ADAM17 with TMI-005 or with ADAM17-directed siRNA counteracts IR-induced and basal ADAM17 activity.
Supplementary Tables 1 - 3 from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Supplementary Table 1 - Genes positively and negatively associated with radiation sensitivity in breast cancer cell lines. Supplementary Table 2 - Genes positively and negatively associated with radiation sensitivity in breast cancer cell lines after training in the clinical dataset with associated outcomes. Supplementary Table 3 - Univariate and Multivariable analysis results for locoregional recurrence in the training and validation datasets for all available clinical and pathologic variable in these datasets.
Supplementary Figure 5 from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Calibration curves with the fitted logistic regression prediction curve using the out-of-bag cross validation (A) and external validation (B) datasets were generated with 95% confidence intervals shown.
Supplementary Figure 5 from Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype
Authors: Mack Stephen C. , Agnihotri Sameer , Bertrand Kelsey C. , Wang Xin , Shih David J. , Witt Hendrik , Hill Nadia , Zayne Kory , Barszczyk Mark , Ramaswamy Vijay , Remke Marc , Thompson Yuan , Ryzhova Marina , Massimi Luca , Grajkowska Wieslawa , Lach Boleslaw , Gupta Nalin , Weiss William A. , Guha Abhijit , Hawkins Cynthia , Croul Sidney , Rutka James T. , Pfister Stefan M. , Korshunov Andrey , Pekmezci Melike , Tihan Tarik , Philips Joanna J. , Jabado Nada , Zadeh Gelareh , Taylor Michael D.
Published: April 2023

Supplementary Figure 5. Assessment of citric acid cycle activity by protein expression analysis of PDHE1a.
Supplementary Figure 1 from Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer
Authors: Speers Corey , Zhao Shuang , Liu Meilan , Bartelink Harry , Pierce Lori J. , Feng Felix Y.
Published: April 2023

Overview of radiation response signature development utilizing intrinsic radiation sensitivity of human breast cancer cell lines.
Table S1 from The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Authors: Choi Stephen Yiu Chuen , Xue Hui , Wu Rebecca , Fazli Ladan , Lin Dong , Collins Colin C. , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

List of Antisense Oligonucleotides (ASOs) and qPCR Primer Sequences used.
Figure S1 from The MCT4 Gene: A Novel, Potential Target for Therapy of Advanced Prostate Cancer
Authors: Choi Stephen Yiu Chuen , Xue Hui , Wu Rebecca , Fazli Ladan , Lin Dong , Collins Colin C. , Gleave Martin E. , Gout Peter W. , Wang Yuzhuo
Published: April 2023

Candidate MCT4-targeting ASOs are able to inhibit cell proliferation and MCT4 expression of LNCaP human prostate cancer cells 48 hours after transfection. A) MCT4 ASOs are able to inhibit LNCaP cell proliferation to levels comparable to those observed with other human prostate cancer cell lines. B) The decrease in cell proliferation is associated with a decrease in MCT4 expression. Taken together, the data suggest that the inhibitory effect of MCT4 ASOs may be more associated with a glycolytic phenotype than with androgen receptor status.
Supplementary Data File from Alterations in Pericyte Subpopulations Are Associated with Elevated Blood–Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer
Authors: Lyle L. Tiffany , Lockman Paul R. , Adkins Chris E. , Mohammad Afroz Shareef , Sechrest Emily , Hua Emily , Palmieri Diane , Liewehr David J. , Steinberg Seth M. , Kloc Wojciech , Izycka-Swieszewska Ewa , Duchnowska Renata , Nayyar Naema , Brastianos Priscilla K. , Steeg Patricia S. , Gril Brunilde
Published: April 2023

Supplemental Tables. Supplemental Tables S1-6. Table S1. Antibodies used for quantification and concentrations. Table S2. Antibodies that could not be quantified in the model systems under fixation conditions used to identify Texas Red dextran permeability. Table S3. Summary statistics for analysis of brain metastases vs. uninvolved brain for each analyzed immunofluorescence marker. Table S4. Summary statistics for analysis of highly permeable vs. poorly permeable brain metastases for each analyzed immunofluorescence marker. Table S5. Antibodies that could not be quantified in human specimens. Table S6: Summary of immunofluorescence analysis of human brain metastasis specimens Supplemental Figures. Supplemental Figures S1-9. Figure S1. Homogenous HER2 staining in a SUM190-BR3 brain metastasis. Figure S2. No significant trend in Claudin-5 expression in three models of brain metastasis. Figure S3. Increased VEGF expression in brain metastasis. Figure S4. Decreased ZO-1 expression in brain metastasis. Figure S5. Decreased AQP4 expression and an alteration in the AQP4 expression pattern in brain metastasis. Figure S6: Heterogeneous trends in Collagen IV expression in three models of brain metastasis. Figure S7: Colocalization of Desmin+ pericytes and CD13+ pericytes with PDGFR-ÃŽÂ². Figure S8: Desmin immunofluorescent staining in human specimens. Figure S9. Examples of immunofluorescent staining in human specimen #5 Supplemental Experimental Procedures. Detailed experimental procedures that were not included in the body of the manuscript. These include SUM190-BR3 cell line derivation, animal experiments, immunofluorescence, image analysis, statistical analysis, and human craniotomy specimen preparation.
Supplemental Figure 1 from Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Authors: Veldman-Jones Margaret H. , Lai Zhongwu , Wappett Mark , Harbron Chris G. , Barrett J. Carl , Harrington Elizabeth A. , Thress Kenneth S.
Published: April 2023

Supplemental Figure 1. Primer/probe details for RT-PCR, NanoString. Assessment of housekeeping genes
Supplemental Figure 5 from High Levels of Antibody that Neutralize B-cell Infection of Epstein–Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma
Authors: Coghill Anna E. , Bu Wei , Nguyen Hanh , Hsu Wan-Lun , Yu Kelly J. , Lou Pei-Jen , Wang Cheng-Ping , Chen Chien-Jen , Hildesheim Allan , Cohen Jeffrey I.
Published: April 2023

Anti-gp350 antibodies among Prevalent NPC, Incident NPC, and Control participants.
Table S4 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Table S4. Univariate Cox regression analysis for OS and DFS in primary and metastatic ccRCC. P-values and HR of significant variables are highlighted in bold font.
Table S3 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Table S3. Survival analysis according to various cut-offs. Log-rank test p-values for CD8+, PD-1+ and LAG-3+ cell densities at the optimal, median and third quartile cut-offs
Supplementary Table 5 from A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia
Authors: Angelini Daniela F. , Ottone Tiziana , Guerrera Gisella , Lavorgna Serena , Cittadini Michela , Buccisano Francesco , De Bardi Marco , Gargano Francesca , Maurillo Luca , Divona Mariadomenica , Noguera Nélida I. , Consalvo Maria Irno , Borsellino Giovanna , Bernardi Giorgio , Amadori Sergio , Venditti Adriano , Battistini Luca , Lo-Coco Francesco
Published: April 2023

Supplementary Table 5. Longitudinal analysis of FLT3-ITDs using patient-specific RQPCR in four AML patients.
Figure S3 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
Authors: Giraldo Nicolas A. , Becht Etienne , Pagès Franck , Skliris Georgios , Verkarre Virginie , Vano Yann , Mejean Arnaud , Saint-Aubert Nicolas , Lacroix Laetitia , Natario Ivo , Lupo Audrey , Alifano Marco , Damotte Diane , Cazes Aurelie , Triebel Frederic , Freeman Gordon J. , Dieu-Nosjean Marie-Caroline , Oudard Stephane , Fridman Wolf H. , Sautès-Fridman Catherine
Published: April 2023

Figure S3. Representative IHC staining of immune checkpoints in ccRCC : Immunohistochemical staining of immune checkpoints on sections from paraffin embedded ccRCC tumors illustrating highly and poorly PD-1 (A) and LAG-3 (B) infiltrated lesions and PD-L1 (C) and PD-L2 (D) positive and negative tumors
Supplementary Figure 1 from Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease
Authors: Hutcheson Jack , Balaji Uthra , Porembka Matthew R. , Wachsmann Megan B. , McCue Peter A. , Knudsen Erik S. , Witkiewicz Agnieszka K.
Published: April 2023

Analysis of lymphocyte and neutrophil infiltration in the TMA cohort and the impact of these factors on patient survival.
Supplementary Data from Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions
Authors: Damelin Marc , Bankovich Alexander , Park Albert , Aguilar Jorge , Anderson Wade , Santaguida Marianne , Aujay Monette , Fong Sarah , Khandke Kiran , Pulito Virginia , Ernstoff Elana , Escarpe Paul , Bernstein Jeffrey , Pysz Marybeth , Zhong Wenyan , Upeslacis Erik , Lucas Judy , Lucas Justin , Nichols Timothy , Loving Kathryn , Foord Orit , Hampl Johannes , Stull Robert , Barletta Frank , Falahatpisheh Hadi , Sapra Puja , Gerber Hans-Peter , Dylla Scott J.
Published: April 2023

Supplementary Data, Materials and Methods
Figure S4 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Authors: Madore Jason , Strbenac Dario , Vilain Ricardo , Menzies Alexander M. , Yang Jeen Y. H. , Thompson John F. , Long Georgina V. , Mann Graham J. , Scolyer Richard A. , Wilmott James S.
Published: April 2023

Melanoma-specific survival Validation Set. PD-L1 negative/CD8A low was associated with worse survival versus PD-L1 positive/CD8A low or PD-L1 positive/CD8A high (p = 0.014; log rank). An outlier case of PD-L1 negative/CD8A high was also observed in the validation set.
Supplementary Materials and Methods from Druggable Oncogene Fusions in Invasive Mucinous Lung Adenocarcinoma
Authors: Nakaoku Takashi , Tsuta Koji , Ichikawa Hitoshi , Shiraishi Kouya , Sakamoto Hiromi , Enari Masato , Furuta Koh , Shimada Yoko , Ogiwara Hideaki , Watanabe Shun-ichi , Nokihara Hiroshi , Yasuda Kazuki , Hiramoto Masaki , Nammo Takao , Ishigame Teruhide , Schetter Aaron J. , Okayama Hirokazu , Harris Curtis C. , Kim Young Hak , Mishima Michiaki , Yokota Jun , Yoshida Teruhiko , Kohno Takashi
Published: April 2023

PDF file - 168KB
Figure S3 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Authors: Madore Jason , Strbenac Dario , Vilain Ricardo , Menzies Alexander M. , Yang Jeen Y. H. , Thompson John F. , Long Georgina V. , Mann Graham J. , Scolyer Richard A. , Wilmott James S.
Published: April 2023

Heat map (z-scores) for all 141 ImmPort identified immune associated genes differentially expressed by PD-L1 status in stage-III melanoma specimens. False discovery rate values (FDR), p-values, and log fold change (logFC) are also listed. The majority of immune genes (64%) were up-regulated in the in the PD-L1 positive groups (PD-L1 <0% of tumor cells).
Figure S1 from PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma
Authors: Madore Jason , Strbenac Dario , Vilain Ricardo , Menzies Alexander M. , Yang Jeen Y. H. , Thompson John F. , Long Georgina V. , Mann Graham J. , Scolyer Richard A. , Wilmott James S.
Published: April 2023

Correlation between PD-L1 gene expression (RNAseq) and PD-L1 immunohistochemistry score (r2 = 0.711, p = 3.33E-09). Green diamonds = PD-L1 negative by immunohistochemistry; Empty diamonds = PD-L1 positive by immunohistochemistry.
Supplementary methods from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Authors: Taube Janis M. , Young Geoffrey D. , McMiller Tracee L. , Chen Shuming , Salas January T. , Pritchard Theresa S. , Xu Haiying , Meeker Alan K. , Fan Jinshui , Cheadle Chris , Berger Alan E. , Pardoll Drew M. , Topalian Suzanne L.
Published: April 2023

Supplementary methods
Supplementary Table S4 from Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
Authors: Taube Janis M. , Young Geoffrey D. , McMiller Tracee L. , Chen Shuming , Salas January T. , Pritchard Theresa S. , Xu Haiying , Meeker Alan K. , Fan Jinshui , Cheadle Chris , Berger Alan E. , Pardoll Drew M. , Topalian Suzanne L.
Published: April 2023

Supplementary Table S4: DAVID clustering of 1660 Illumina probes up-regulated at least 2-fold in PD-L1+ melanomas
Supplimentary Methods and Figure Legends from Inhibition of FoxM1-Mediated DNA Repair by Imipramine Blue Suppresses Breast Cancer Growth and Metastasis
Authors: Rajamanickam Subapriya , Panneerdoss Subbarayalu , Gorthi Aparna , Timilsina Santosh , Onyeagucha Benjamin , Kovalskyy Dmytro , Ivanov Dmitri , Hanes Martha A. , Vadlamudi Ratna K. , Chen Yidong , Bishop Alexander J. , Arbiser Jack L. , Rao Manjeet K.
Published: April 2023

Supplimentary Methods and Figure Legends
Supplementary Table 1 from Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
Authors: Venderbosch Sabine , Nagtegaal Iris D. , Maughan Tim S. , Smith Christopher G. , Cheadle Jeremy P. , Fisher David , Kaplan Richard , Quirke Philip , Seymour Matthew T. , Richman Susan D. , Meijer Gerrit A. , Ylstra Bauke , Heideman Danielle A.M. , de Haan Anton F.J. , Punt Cornelis J.A. , Koopman Miriam
Published: April 2023

Patient characteristics of the pooled data set in relation to MMR and BRAF mutation status.